Delana Jones
Medical · Dallas, TXNPI 1144417817
Payments from drug & device makers
Across 353 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$829
- Pfizer$653
- Lundbeck LLC$367
- Teva Pharmaceuticals USA, Inc.$351
- Impel Pharmaceuticals LLC$347
- plus $1K from 16 others
What the payments were for
- Food & beverage$5,588100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 110 | $1,557 |
| Lilly USA, LLC | 63 | $829 |
| Pfizer | 46 | $653 |
| Lundbeck LLC | 20 | $367 |
| Teva Pharmaceuticals USA, Inc. | 13 | $351 |
| Impel Pharmaceuticals LLC | 17 | $347 |
| Biohaven Pharmaceutical Holding Company Ltd. | 23 | $282 |
| Upsher-smith Laboratories LLC | 11 | $234 |
| Amgen | 11 | $203 |
| Biohaven Pharmaceuticals, Inc. | 7 | $166 |
| Axsome Therapeutics, Inc. | 8 | $153 |
| Scilex Pharmaceuticals Inc. | 5 | $95 |
| Impel Pharmaceuticals Inc. | 4 | $86 |
| Tonix Medicines, Inc. | 5 | $77 |
| Amneal Pharmaceuticals LLC | 2 | $39 |
| Novartis | 2 | $31 |
| SK Life Science, Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Aquestive Therapeutics, Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
How this compares
$5,588 in reported general payments places this provider in the 85th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 54 | $83,553 |
| Aimovig AutoinjectorErenumab-Aooe | 70 | $66,268 |
| Nurtec OdtRimegepant Sulfate | 21 | $42,856 |
| Emgality PenGalcanezumab-Gnlm | 42 | $35,426 |
| QuliptaAtogepant | 17 | $23,633 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $8,922 |
| Eletriptan HbrEletriptan Hydrobromide | 26 | $2,127 |
| Sumatriptan Succinate | 99 | $2,102 |
| RizatriptanRizatriptan Benzoate | 40 | $890 |
| Propranolol Hcl ErPropranolol Hcl | 13 | $787 |
| Nortriptyline Hcl | 38 | $733 |
| Gabapentin | 33 | $690 |
| Tizanidine Hcl | 41 | $394 |
| Topiramate | 56 | $377 |
| Amitriptyline Hcl | 39 | $373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $1,557 | $107,18671 claims |
| PfizerNurtec Odt | $653 | $42,85621 claims |
| Upsher-smith Laboratories LLCTopiramate | $234 | $37756 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,490 medical providers in Texas.
Other medical in Dallas
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
- Andrew GarzaDallas$43K
- Alyssa SpiegelDallas$18K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.